[4] – Balcom Alexandra (CIK 0001862147)

Rhea-AI Filing Summary

Nuvalent (NUVL) reported insider transactions by its Chief Financial Officer. On 10/13/2025 and 10/14/2025, the CFO exercised employee stock options and sold shares pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.

On 10/13, options for 6,875 shares at $6.89 and 13,125 shares at $18.93 were exercised, followed by sales totaling 20,000 shares at weighted-average prices within disclosed ranges of $87.15–$89.28. On 10/14, 20,000 options at $18.93 were exercised and 20,000 shares were sold at weighted-average prices within $85.17–$89.12. Following these transactions, the CFO beneficially owned 61,734 Class A shares directly and 30,662 options remained outstanding.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Balcom Alexandra

(Last) (First) (Middle)

C/O NUVALENT, INC.

ONE BROADWAY, 14TH FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvalent, Inc. [ NUVL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	10/13/2025		M(1)		6,875	A	$6.89	68,609	D
Class A Common Stock	10/13/2025		M(1)		13,125	A	$18.93	81,734	D
Class A Common Stock	10/13/2025		S(1)		6,138	D	$87.9(2)	75,596	D
Class A Common Stock	10/13/2025		S(1)		12,266	D	$88.73(3)	63,330	D
Class A Common Stock	10/13/2025		S(1)		1,596	D	$89.22(4)	61,734	D
Class A Common Stock	10/14/2025		M(1)		20,000	A	$18.93	81,734	D
Class A Common Stock	10/14/2025		S(1)		12,280	D	$85.75(5)	69,454	D
Class A Common Stock	10/14/2025		S(1)		5,820	D	$86.63(6)	63,634	D
Class A Common Stock	10/14/2025		S(1)		1,700	D	$87.67(7)	61,934	D
Class A Common Stock	10/14/2025		S(1)		200	D	$88.9(8)	61,734	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.89	10/13/2025		M(1)			6,875	(9)	04/29/2031	Class A Common Stock	6,875	$0.00	35,976	D
Stock Option (Right to Buy)	$18.93	10/13/2025		M(1)			13,125	(10)	01/04/2032	Class A Common Stock	13,125	$0.00	50,662	D
Stock Option (Right to Buy)	$18.93	10/14/2025		M(1)			20,000	(10)	01/04/2032	Class A Common Stock	20,000	$0.00	30,662	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.15 to $88.14, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (8) of this Form 4.

3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.15 to $89.14, inclusive.

4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.15 to $89.28, inclusive.

5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.17 to $86.16, inclusive.

6. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.22 to $87.21, inclusive.

7. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.22 to $88.20, inclusive.

8. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.67 to $89.12, inclusive.

9. The shares underlying this option vest as follows: 25% of the shares vested on April 29, 2022, and the remainder have vested or shall vest over the three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

10. The shares underlying this option vest as follows: 25% of the shares vested on January 4, 2023, and the remainder have vested or shall vest over the three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

	/s/ Nathan N. McConarty, attorney-in-fact	10/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Nuvalent (NUVL) disclose?

The CFO exercised stock options and sold shares on 10/13/2025 and 10/14/2025 under a Rule 10b5-1 plan.

How many shares did the NUVL CFO exercise and sell?

On 10/13, options for 6,875 and 13,125 shares were exercised; 20,000 shares were sold. On 10/14, 20,000 options were exercised and 20,000 shares were sold.

At what prices were the NUVL shares sold?

Sales were reported at weighted-average prices within ranges of $87.15–$89.28 on 10/13 and $85.17–$89.12 on 10/14.

What are the exercise prices and expirations of the options?

Options exercised carried exercise prices of $6.89 (expiring 04/29/2031) and $18.93 (expiring 01/04/2032).

How many NUVL shares does the CFO own after these trades?

Following the reported transactions, the CFO directly owned 61,734 Class A shares and had 30,662 options remaining.

Were these trades pre‑planned?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on December 12, 2024.